Effect of meglumine antimoniate on the pancreas during treatment of visceral leishmaniasis in children

Medical Science Monitor

Volumn 15, Issue 6, 2009, Pages

  Shahian, Mozhgan ^a   Alborzi, Abdolvahab ^b  

^a SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Children; Meglumine antimoniate; Pancreatitis; Visceral leishmaniasis

Indexed keywords

AMYLASE; MEGLUMINE ANTIMONATE; TRIACYLGLYCEROL LIPASE;

ACUTE PANCREATITIS; AMYLASE BLOOD LEVEL; ARTICLE; CHILD; CLINICAL ARTICLE; DRUG EFFECT; FEMALE; HUMAN; HYPERAMYLASEMIA; INFANT; MALE; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; VISCERAL LEISHMANIASIS;

ANTIPROTOZOAL AGENTS; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INFANT; LEISHMANIASIS, VISCERAL; MALE; MEGLUMINE; ORGANOMETALLIC COMPOUNDS; PANCREAS;

EID: 66749164295     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. World Health Organization: Communicable Diseases, Kala azar: Kala azar status in SEA Region 2007
2. Alborzi A, Rasouli M, Shomsizadeh A: Leishmania tropica - isolated patient with visceral leishmaniasis in southern Iran. Am J Trop Med Hyg, 2006; 74(2): 306-307 (Pubitemid 46774345)
3. Gradoni L, Bryceson A, Desjeux P: Treatment of Mediterranean visceral leishmaniasis. Bull World Health Organ, 1995; 73: 191-197
4. Di Giorgio C, Delmas F, Ollivier E et al: In vitro activity of the B-carboline alkaloids harmane, harmine, and harmaline toward parasites of the species leishmania infantum. Experimental Parasitology, 2004; 106: 67-74
5. Sunder S, Rai M: Treatment of visceral leishmaniasis. Expert Opin Pharmacother, 2005; 6(16): 2821-2829 (Pubitemid 43009545)
6. Mittal MK, Rai S, Ashutosh et al: Characterization of natural antimony resistance in Leishmania Donovani isolates. Am J Trop Med Hyg, 2007; 76(4): 681-688
7. Ashutosh, Gupta S, Ramesh et al: Use of Leishmania donovani field isolates Expressing luciferase reporter gene in in vitro drug screening. Antimicrob Agents Chemother, 2005; 49: 3776-3783 (Pubitemid 41233031)
8. Minodier P, Noel G, Blanc P et al: Treatment of visceral leishmaniasis in children. Med Trop(Mars), 2007; 67(1): 73-78 (Pubitemid 350157238)
9. Kafetzis DA: An overview of paediatric leishmaniasis. J Postgrad Med, 2003; 49(1): 31-38 (Pubitemid 36758266)
10. Donovan KL, White AD, Cooke DA, Fisher DJ: Pancreatitis and palindromic arthropathy with effusions associated with sodium stibogluconate treatment in a renal transplant recipient. J Infect, 1990; 21: 107-110 (Pubitemid 20261034)
11. Laguna F, Soriano V, Gonzales-Lahoz JM: Misdiagnosis of pancreatitis in patients receiving treatment with pentavalent antimonial agents. Clin Infec Dis, 1994; 19: 978-979 (Pubitemid 24368852)
12. Kuyucu N, Kara C, Bakirtac A, Tezic T: Successful treatment of visceral Leishmaniasis with allopurinol plus ketoconazole in a infant who developed pancreatitis caused by meglumine antimoniate. Pediatr Infect Dis J, 2001; 20(4): 455-457 (Pubitemid 32294764)
13. Karimi A, Alborzi I, Mahmodi MR et al: Short course anti- Leishmania therapy in children with visceral leishmaniasis. Iranian J of Medical Sciences, 1998; 23: 6-10 (Pubitemid 29054757)
14. Delgado J, Macias J, Pineda JA et al: High frequency of serious side effects from meglumine antimoniate given without an upper limit dose for the treatment of visceral leishmaniasis in human immunodeficiency virus type 1-infected patients. Am J Trop Med Hyg, 1999; 61(5): 766-769
15. Halim MA, Alfuragh O, Kalin ME: Successful treatment of visceral leishmaniasis with allopurinol plus ketoconazole in a renal transplant recipient after the occurrence of pancreatitis due to stibogluconate. Clin Infet Dis, 1993; 16: 397-399 (Pubitemid 23066949)
16. Mcbride Mo, Linney M, Davidson RN: Pancreatic necrosis following treatment of Leishmaniasis with sodium stibogluconate. Clin Infect Dis, 1995; 21: 710
17. Torrus D, Massa B, Boix V et al: Meglumine antimoniate-induced pancreatitis. Am J Gastroenterol, 1996; 91: 820-821 (Pubitemid 26117984)
18. Gasser RA Jr, Magill AJ, Oster CN et al: Pancreatitis induced by pentavalnet antimonial agents during treatment of Leishmaniasis. Clin Infect Dis, 1994; 18: 83-90 (Pubitemid 24025920)
19. Chulav YD, Bhatt SM: A comparison of 3 dosage regimens of sodium stibogluconate in the treatment of visceral Leishmaniasis in Kenya. J Infect Dis, 1983: 148(1): 148-155
20. Schubach RO, Marzochi KF, Moreira JS et al: Retrospective study of 151 patients with cutaneous leishmaniasis treated with meglumine antimoniate. Revista da Sociedade Brasileira de Medicina Tropical, 2005; 38(3): 213-217 (Pubitemid 40675628)
21. Berman JD: Chemotherapy for leishmaniasis: biochemical mechanisms, clinical efficacy, and future strategies. Reviews Infectious Diseases, 1988; 10: 560-586
22. Azeredo-Coutinho RB, Mendonca SC, Callahan H et al: Sensitivity of leishmaniasis braziliensis promastigotes to meglumine antimoniate is higher than that of other leishmania species and correlates with response to therapy in American tegumentary leishmaniasis. J Parasitol, 2007; 93(3): 688-693 (Pubitemid 47036094)
23. Banerjee A, Patel K, Grainger SL: Drug-induced acute pancreatitis: a critical review. Med Toxical Adverse Drug Experience, 1989; 4: 186-198 (Pubitemid 19134521)
24. th ed. BC Decker Inc., 2004; 1586-1590
25. th ed. McGraw-Hill, 2005; 1891-1906
26. Murthy UK, De Gregorio F, Oates RP: Hyperamylasemia in patients with the acquired immunodeficiency syndrome. Am J Gastroenterol, 1992; 87: 332-336
27. Chehter EZ, Longo MA, Laudanna AA, Duarte MIS: Pancreatic involvement in co-infection visceral Leishmaniasis and HIV: histological and ultrastructural aspects. Rev Inst Med Trop S Paulo, 2001; 43(2): 1-7 (Pubitemid 33622292)
28. Lambertucci JR, Franca BM, Queiroz EM: Acute pancreatitis caused by meglumine antimoniate given for the treatment of visceral leishmaniasis. Revista da Sociedade Brasileira de Medicina Tropical, 2004; 37: 74-75 (Pubitemid 38279915)